



PTO/SB/08 Equivalent

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Multiple sheets used when necessary)	Application No.	10/719,619
	Filing Date	November 20, 2003
	First Named Inventor	Sallberg, et al.
	Art Unit	1648
	Examiner	Bao Q. Li
SHEET 1 OF 4		Attorney Docket No. TRIPEP.23AUSC2

# U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/BL/	1	4,215,051	7/29/1980	Schroeder et al.	
	2	4,376,110	3/8/1983	David et al.	
	3	4,486,530	12/4/1984	David et al.	
	4	4,683,195	7/28/1987	Mullis et al.	
	5	4,683,202	7/28/1987	Mullis, Kary B.	
	6	4,818,540	4/4/1989	Chien, et al.	
	7	4,873,191	10/10/1989	Wagner et al.	
	8	4,965,188	10/23/1990	Mullis, Kary B.	
	9	5,143,854	9/1/1992	Pirung et al	
	10	5,290,678	3/1/1994	Jackowski	
	11	5,322,770	6/21/1994	Gelfand	
	12	5,412,087	5/2/1995	McGall et al.	
	13	5,593,972	1/14/1997	Weiner et al.	
	14	5,604,105	2/18/1997	Jackowski	
	15	5,710,008	1/20/1998	Jackowski	
	16	5,739,118	4/14/1998	Carrano et al.	
	17	5,744,358	4/28/1998	Jackowski	
	18	5,747,274	5/5/1998	Jackowski	
	19	5,847,101	12/1/1998	Okayama et al	
	20	5,879,904	3/1/1999	Brechot et al.	
	21	6,153,421	11/1/2000	Yanagi et al.	
	22	2004/0092730	5/13/2004	Sallberg, Matti	
	23	08/008,342	1/26/1993	Weiner et al	
	24	08/029,336	3/11/1993	Weiner et al.	

Examiner Signature /Bao Li/ Date Considered 05/21/2007

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Multiple sheets used when necessary)</i>	Application No.	10/719,619
	Filing Date	November 20, 2003
	First Named Inventor	Sallberg, et al.
	Art Unit	1648
SHEET 2 OF 4		Examiner
		Bao Q. Li
		Attorney Docket No.
		TRIPEP.23AUSC2

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
/BL/	25	WO 90/15070	12/13/1990	Affymax Technologies N.V.		
	26	WO 92/10092	6/25/1992	Affymax Technologies N.V.		
	27	WO 94/11530	5/26/1994	Trustees of Boston University		
	28	WO 94/12305	6/9/1994	Gühring, et al.		
	29	WO 95/11995	5/4/1995	Affymax Technologies N.V.		
	30	WO 96/09805	4/4/1996	Zonagen, INC.		
	31	WO 96/33739	10/31/1996	Smithline Beecham Biologicals S.A.		
	32	WO 97/29212	8/14/1997	Affymetrix, Inc.,		
	33	WO 97/31256	8/28/1997	Louisiana State University		
	34	WO 97/47358	12/18/1997	Merck & Co., Inc.,		
	35	WO 98/34640	8/13/1998	Merck & Co., Inc.,		
↓	36	WO 03/031588	4/17/2003	Merck & Co., Inc.,		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/BL/	37	Abignani et al., "Perspectives for a vaccine against hepatitis C virus," Journal of Hepatology, 31: (suppl. 1):259-263 (1999)	
	38	Andre et al., "Increased Immune Response Elicited by DNA Vaccination with a Synthetic gp120 Sequence with Optimized Codon Usage," Journal of Virology, 72(2):1497-1503 (1998)	
	39	Bitter et al., <i>Methods in Enzymol.</i> , 153:516-544 (1987)	
	40	BLASTN 2.2.9., May 1, 2004	
	41	Chang et al., <i>Aliment Pharmacol Ther.</i> 2002 Sep; 16(9): 1623-1632	
	42	Chiang et al., "Enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response by ribavirin correlates with the increased level of IL-2," <i>Vaccine Strategies Against Microbial Pathogens</i> , 42:11-42:16, p. A949 April 20, 2000	
↓	43	Colberre-Garapin, et al., "A new dominant hybrid selective marker for higher eukaryotic cells," <i>J. Mol. Biol.</i> 150:1 (1981)	

Examiner Signature	/BL/	Date Considered	05/21/2007
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Multiple sheets used when necessary)</i>	Application No.	10/719,619
	Filing Date	November 20, 2003
	First Named Inventor	Sallberg, et al.
	Art Unit	1648
SHEET 3 OF 4		Attorney Docket No. TRIPEP.23AUSC2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/BL/	44	Cote et al., "Generation of human monoclonal antibodies reactive with cellular antigens" <i>Proc Natl. Acad. Sci.</i> , 80:2026-2030 (1983)	
	45	DATABASE GENBANK [Online] 12/02/94, retrieved from NCBI Database accession no.I06434, XP002278035.	
	46	DATABASE REGISTRY [Online] No. 511600-20-7, XP02278058 abstract & WO 03/031588A, 04/17/03, Seq ID No.1, 10 and 11 Claims	
	47	Davis et al., <i>Human Gene Therapy</i> , 4(6):733 (1993)	
	48	Engvall, E., <i>Meth. Enzymol</i> , 70:419 (1980)	
	49	Fodor et al., <i>Science</i> , 251:767-773 (1991)	
	50	Forns et al., "Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees," <i>PNAS</i> , vol. 97, No. 24, pp. 13318-113323, (2000)	
	51	Hahm et al., "NS3-4A of Hepatitis C Virus is a Chymotrypsin-Like Protease," <i>Journal of Virology</i> , The American Society for Microbiology, 69(4): 2534-2539 (1995).	
	52	Heagy et al., <i>J. Clin. Invest.</i> 1991, Vol. 87, pp. 1916-1924	
	53	Hosoya et al., <i>J. INF. Dis.</i> , 168:641-646 (1993)	
	54	Houghten et al., <i>Proc. Natl. Acad. Sci. USA</i> , 82:51:32 (1985)	
	55	Hultgren et al., <i>Clin. Diagn. Lab. Immunol.</i> 4:630-632 (1997)	
	56	Huse W.D. et al. <i>Science</i> 256:1275-1281 (1989)	
	57	Hutchison et al., <i>Proc. Natl. Acad. Sci. USA</i> 253:6551 (1978)	
	58	Janknecht, et al., <i>Proc. Natl. Acad. Sci. USA</i> 88:8972-8976 (1991)	
	59	Kozbor et al., <i>Immunol Today</i> 4:72 (1983)	
	60	Kumar et al., "Hepatitis C virus genomic RNA for polyprotein gene," <i>Journal of Hepatology</i> , 7:459-465 (2000)	
	61	Lazdina et al., "Humoral and CD4 <sup>+</sup> T helper (th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes TH 1-like responses more effectively as a DNA-Based immunogen than as a recombinant protein," <i>Journal of General Virology</i> , 82:1299-1308 (2001)	
↓	62	Lo, <i>Mol. Cell. Biol.</i> 3:1803-1814 (1983)	

Examiner Signature	/Bao Li/	Date Considered	05/21/2007
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Multiple sheets used when necessary)</i>	Application No.	10/719,619
	Filing Date	November 20, 2003
	First Named Inventor	Sallberg, et al.
	Art Unit	1648
SHEET 4 OF 4		Examiner Bao Q. Li
		Attorney Docket No. TRIPEP.23AUSC2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/BL/	63	Logan & Shenk, <i>Proc. Natl. Acad. Sci. USA</i> 81:3655-3659 (1984)	
	64	Lowy, et al., <i>Cell</i> 22:817 (1980)	
	65	Morrison et al. <i>Proc. Natl. Acad. Sci. USA</i> 81:6851-6855 (1984)	
	66	Mulligan & Berg, <i>Proc. Natl. Acad. Sci. USA</i> 78:2072 (1981)	
	67	NCBI, Genbank, M32084. Hepatitis C Virus. . . [GI:32987] August 02, 1993	
	68	O'Hare, et al., <i>Proc. Natl. Acad. Sci. USA</i> 78:1527 (1981)	
	69	Orlandi et al., <i>Proc. Natl. Acad. Sci.</i> 86: 3833-3837 (1989)	
	70	Rudikoff et al., <i>Immunology</i> 1982, Vol. 79, pp. 1979-1983	
	71	Ruther et al., <i>EMBO J.</i> , 2:1791 (1983)	
	72	Santerre et al., <i>Gene</i> . 30:147 (1984)	
	73	Steigerwald-Mullen et al., <i>J. Virol.</i> 2000, Vol. 74, No. 15, pp. 6748-6759	
	74	Thompson et al., <i>Cell</i> 56:313-321 (1989)	
	75	Townsend et al., <i>J. Virol.</i> 71:3365 (1997)	
	76	Van der Putten et al., <i>Proc. Natl. Acad. Sci., USA</i> 82:6148-6152 (1985)	
	77	Wigler et al., <i>Cell</i> 11:223 (1977)	
	78	Wigler et al., <i>Proc. Natl. Acad. Sci. USA</i> 77:3567 (1980)	
↓	79	Winter G. and Milstein C; <i>Nature</i> 349:293-299 (1991)	

333889  
012207

Examiner Signature /Bao Li/	Date Considered 05/21/2007
<b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
TRIPEP.23AUSC2APPLICATION NO.  
10/719,619INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Sällberg et al.FILING DATE  
November 20, 2003GROUP  
Unknown

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	86	EP 0 398 748	01/09/02	European Patent Office				
	87	WO 02/13855	02/21/02	WIPO				
	88	WO 02/14362	02/21/02	WIPO				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	89	AASLD Abstracts 940, "Hepatitis C Virus NS5A Sequence Configuration does not Predict Response to Induction Interferon Plus Ribavirin," <i>Hepatology</i> , p. 394A (2000).
	90	Abregnani et al., "Perspectives for a vaccine against hepatitis C virus," <i>Journal of Hepatology</i> , 31: (suppl. 1):259-263 (1999).
	91	Bartenschlager et al., "Substrate Determinants for Cleavage in cis and in trans by the Hepatitis C Virus NS3 Proteinase," <i>Journal of Virology</i> , pp. 198 - 205, (1995).
	92	Chen et al., "Human and Murine Antibody Recognition is Focused on the ATPase/Helicase, but not the Protease Domain of the Hepatitis C Virus Nonstructural 3 Protein," <i>Hepatology</i> , 28(1):219-224 (1998).
	93	Chen et al., "Detection of Hepatitis C Virus RNA in the Cell Fraction of Saliva Before and After Oral Surgery," <i>J. Med. Virol.</i> , 43:223-226 (1995).
	94	Chiang et al., "Enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response by ribavirin correlates with the increased level of IL-2," <i>Vaccine Strategies Against Microbial Pathogens</i> , 42:11-42.16, p. A949 (date unknown). (2000)
	95	Cotonat et al., "Pilot Study of Combination Therapy with Ribavirin and Interferon Alfa for the Retreatment of Chronic Hepatitis B e Antibody-Positive Patients," <i>Hepatology</i> , 31(2):502-506 (2000).
	96	Cramp et al., "Hepatitis C Virus-Specific T-Cell Reactivity During Interferon and Ribavirin Treatment in Chronic Hepatitis C," <i>Gastron. Enterol.</i> , 118:346-355 (2000)
	97	Encke et al., "DNA Vaccines," <i>Intervirology</i> , 42:117-124, (1999)
	98	Encke et al., "Genetic Immunization Generates Cellular and Humoral Immune Responses Against the Nonstructural Proteins of the Hepatitis C Virus in a Murine Model," <i>Journal of Immunology</i> , 161:4917-4923 (1998).
	99	Diepolder et al., "Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection," <i>Lancet</i> , 346(8981):1006-1007. (1995)
	100	Fang et al., "Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level," <i>Journal of Hepatology</i> , 33(5):791-798 (2000).
	101	Forns et al., "Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees," <i>PNAS</i> , vol. 97, no. 24, pp. 13318-113323, (2000).
	102	Gordon et al., "Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations," <i>Journal of Infectious Diseases</i> , 181(1):42-50. (2000)
	103	Grakoui et al., "A second hepatitis C virus-encoded proteinase," <i>Proc. Natl. Acad. Sci USA</i> , 90:10583-10587, (1993).
	104	Hsu et al., "Prospects for a Hepatitis C Virus Vaccine," <i>Clin Liver Dis</i> , 3(4):901-915 (1999).
	105	Huffman et al., "In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses," <i>Antimicrob. Agents. Chemother.</i> , 3(2):235 (1973).
	106	Hultgren et al., <i>J. Gen. Virol.</i> , 79:2381-2391 (1998)
	107	Jin et al., "Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA Helicase," <i>Arch. Biochem. Biophys.</i> , 323:47-53 (1995).
	108	Kakumu et al., "Pilot Study of Ribavirin and Interferon- for Chronic Hepatitis B," <i>Hepatology</i> , 18(2):258-263 (1993).

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.